Shares of Concord Medical Services Hldg Ltd (NYSE:CCM) have been given a consensus broker rating score of 3.70 (Sell) from the one brokers that provide coverage for the company, Zacks Investment Research reports. One research analyst has rated the stock with a sell rating.
Brokerages have set a 1-year consensus price target of $3.00 for the company and are anticipating that the company will post $0.01 EPS for the current quarter, according to Zacks. Zacks has also assigned Concord Medical Services an industry rank of 30 out of 257 based on the ratings given to related companies.
Separately, Zacks Investment Research upgraded Concord Medical Services from a “hold” rating to a “buy” rating and set a $3.50 price objective for the company in a research report on Wednesday, September 12th.
About Concord Medical Services
Concord Medical Services Holdings Limited, through its subsidiaries, operates a network of radiotherapy and diagnostic imaging centers in the People's Republic of China. The company's services comprise linear accelerators external beam radiotherapy, gamma knife radiosurgery, head gamma knife systems, body gamma knife systems, CyberKnife robotic radiosurgery system, proton beam therapy systems, and diagnostic imaging services.
See Also: Intrinsic Value
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Concord Medical Services Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Concord Medical Services and related companies with MarketBeat.com's FREE daily email newsletter.